Cargando…

Pan-cancer analysis of the effect of biopsy site on tumor mutational burden observations

BACKGROUND: Tumor mutational burden (TMB) has been proposed as a predictive biomarker of response to immunotherapy. Efforts to standardize TMB scores for use in the clinic and to identify the factors that could impact TMB scores are of high importance. However, the biopsy collection site has not bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papillon-Cavanagh, Simon, Hopkins, Julia F., Ramkissoon, Shakti H., Albacker, Lee A., Walsh, Alice M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053207/ https://www.ncbi.nlm.nih.gov/pubmed/35602225 http://dx.doi.org/10.1038/s43856-021-00054-8

Ejemplares similares

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
por: Papillon-Cavanagh, Simon, et al.
Publicado: (2020)

Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden
por: Yuan, Hong, et al.
Publicado: (2021)

A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres
por: Sharaf, Radwa, et al.
Publicado: (2022)

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
por: Wang, Victoria E., et al.
Publicado: (2017)

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
por: Joshi, Rushikesh S., et al.
Publicado: (2022)

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
por: Parikh, Ankur R, et al.
Publicado: (2018)

Mutations in the TERC template sequence can be incorporated into the telomeres of human tumors
por: Sharaf, Radwa, et al.
Publicado: (2022)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Next-Generation Sequencing in Order to Better Characterize a BRCA Variant of Uncertain Significance
por: Sorscher, Steven, et al.
Publicado: (2017)

Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors
por: Fontebasso, Adam M., et al.
Publicado: (2014)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort
por: Li, Yuan, et al.
Publicado: (2020)

Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes
por: Wiecek, Anna Julia, et al.
Publicado: (2021)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers
por: Girard, Nicolas, et al.
Publicado: (2022)

Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
por: Wang, Hai-Yun, et al.
Publicado: (2021)

MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancer
por: Yang, Yue, et al.
Publicado: (2020)

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers
por: Pham, Timothy V., et al.
Publicado: (2021)

Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: A Chinese pan‐cancer cohort
por: Xu, Enwu, et al.
Publicado: (2021)

Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
por: Johnson, Adrienne, et al.
Publicado: (2017)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Current and emerging applications of liquid biopsy in pan-cancer
por: Wang, Wenxiang, et al.
Publicado: (2023)

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
por: Jung, Jaeyun, et al.
Publicado: (2023)

CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion
por: Williams, Erik A., et al.
Publicado: (2020)

Li‐Fraumeni versus Pseudo‐Li‐Fraumeni Syndrome: Key Insights for Interpreting Next‐Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes
por: Sorscher, Steven, et al.
Publicado: (2017)

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
por: Sivapiragasam, Abirami, et al.
Publicado: (2020)

Colon biopsies: benefit or burden?
por: Morarasu, Stefan, et al.
Publicado: (2019)

Talar Body Fracture With Closed Pan-Talar Dislocation
por: Patra, Saroj K, et al.
Publicado: (2021)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate
por: Zhang, Wensheng, et al.
Publicado: (2017)

Analysis of solid tumor mutation profiles in liquid biopsy
por: Balaji, Sai A., et al.
Publicado: (2018)

Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death
por: Hieronymus, Haley, et al.
Publicado: (2018)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma
por: Xie, Lu, et al.
Publicado: (2021)

Spontaneous mutations in the single TTN gene represent high tumor mutation burden
por: Oh, Ji-Hye, et al.
Publicado: (2020)

Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects
por: Ishiyama, Noboru, et al.
Publicado: (2023)

Tumor mutation burden and recurrent tumors in hereditary lung cancer
por: Hsu, Yi‐Chiung, et al.
Publicado: (2019)

A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
por: Gao, Guanghui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7f6sc41s8aqfh44akgkf67ikcj